Navigation Links
Inverness Medical Innovations Announces Second Quarter 2008 Results
Date:7/29/2008

income that have a significant positive or negative impact on results yet

do not occur on a consistent or regular basis in its business. In

determining whether a particular item meets one of these criteria,

management considers facts and circumstances that it believes are

relevant. Management believes that excluding such charges and income from

income or loss allows investors and management to evaluate and compare the

Company's operating results from continuing operations from period to

period in a meaningful and consistent manner. Due to the frequency of

their occurrence in its business, the Company does not adjust net income

or loss for the costs associated with litigation, including payments made

or received through settlements. It should be noted that "net income or

loss on an adjusted cash basis" is not a standard financial measurement

under accounting principles generally accepted in the United States of

America ("GAAP") and should not be considered as an alternative to net

income or loss or cash flow from operating activities, as a measure of

liquidity or as an indicator of operating performance or any measure of

performance derived in accordance with GAAP.

(b) Amortization expense of $95.0 million and $16.6 million in the first

six months of 2008 and 2007 GAAP results, respectively, including $23.7

million and $6.3 million charged to cost of sales, $1.8 million and $1.5

million charged to research and development and $69.1 million and $8.6

million charged to selling, general and administrative, in the respective

periods, with $0.4 million and $0.2 million charged through equity

earnings of unconsolidated entities, net of tax during the six months

ended June 30, 3008 and 2007, respectively.

(c) Restructuring charges associated with the decision to close facilities

of $39.9 million and $1.0 million in
'/>"/>

SOURCE Inverness Medical Innovations, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16

Related biology technology :

1. Inverness Medical Innovations Agrees to Acquire Panbio Ltd.
2. Inverness - Chemogen Establish Exclusive License for TB Antibodies
3. Inverness Medical Innovations Announces Proposed Public Offering of Common Stock
4. Inverness Medical Innovations Agrees to Acquire ParadigmHealth
5. Inverness Medical Innovations Acquires ParadigmHealth
6. Inverness Medical Innovations to Participate at JP Morgan Healthcare Conference on January 8, 2008
7. Inverness Medical Innovations to Participate at 2008 Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference on February 5, 2008
8. Correction to Press Release Dated January 31, 2008: Inverness Medical Innovations to Participate at 2008 Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference on February 5, 2008
9. Inverness Medical Innovations Completes Acquisition of BBI Holdings Plc
10. Inverness Medical Innovations Announces Fourth Quarter 2007 Results
11. Inverness Medical Innovations to Participate at Bank of America 2008 Smid Cap Conference on March 26, 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... , July 30, 2015   Aratana Therapeutics, ... therapeutics company focused on the licensing, development and ... today announced that its strategic partner VetStem Biopharma, ... confirmation study of AT-016, an adipose-derived allogeneic stem ... treatment of osteoarthritis pain in dogs. ...
(Date:7/30/2015)...  With over 60,000 customers across the globe, ISN improves the efficiency and effectiveness ... more than 60,000 safe and reliable contractors in over 80 countries. ... ... Over 60,000 Worldwide Customers In ... Headquartered in Dallas, TX , ISN has additional ...
(Date:7/30/2015)... HIGHLIGHTS:Q2 2015 Results (all changes ... Reported sales were $697 million compared to $701 million ... by 8%, and changes in foreign currency exchange rates ... 1%. , By business unit, organic sales growth ... in SAFC Commercial. , Reported diluted EPS was ...
(Date:7/30/2015)... New York, NY (PRWEB) , ... July 30, 2015 , ... As part of its ... raw material and technical service business units, Whitehouse Laboratories is pleased ... facility will be adjacent to the Container Center of Excellence and will be strictly dedicated ...
Breaking Biology Technology:Aratana Therapeutics Announces Positive Pilot Field Study for AT-016 2Aratana Therapeutics Announces Positive Pilot Field Study for AT-016 3Aratana Therapeutics Announces Positive Pilot Field Study for AT-016 4Aratana Therapeutics Announces Positive Pilot Field Study for AT-016 5ISN Reaches Over 60,000 Worldwide Customers 2ISN Reaches Over 60,000 Worldwide Customers 3Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 2Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 3Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 4Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 5Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 6Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 7Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 8Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 9Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 10Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 11Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 12Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 13Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 14Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 15Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 16Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 17Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 18Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 19Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 20Whitehouse Labs Formally Announces Plans to Open a Microbiological Laboratory 2
... Process for Picoplatin -SOUTH SAN FRANCISCO, Calif., May 12 ... a biopharmaceutical company focused on innovative oncology therapies, today ... will present at the BIO International Convention on Tuesday, ... Mr. Martell will provide an overview of the ...
... HILLS, Mass., May 12 Joseph F. Finn, Jr., ... Therapeutics, Inc. ("Prospect") have been assigned to him for ... is a carbohydrate molecule designed to inhibit the activity ... a broad range of human cancers and whose over-expression ...
... Biodiesel industry leader to acquire 105 MGY of additional capacity in ... ... Ames, Iowa (Vocus) May 12, 2009 -- Renewable Energy Group® ... commercial-scale biodiesel plants. Western Iowa Energy, which operates a 30 MGY ...
Cached Biology Technology:Poniard Pharmaceuticals to Present at the 2009 BIO International Convention 2Poniard Pharmaceuticals to Present at the 2009 BIO International Convention 3Prospect Therapeutics, Inc. Assigns All Its Assets to Joseph F. Finn, Jr., C.P.A. for the Benefit of Its Creditors 2REG Signs Agreement with Three Biodiesel Plants to Consolidate 2REG Signs Agreement with Three Biodiesel Plants to Consolidate 3REG Signs Agreement with Three Biodiesel Plants to Consolidate 4REG Signs Agreement with Three Biodiesel Plants to Consolidate 5REG Signs Agreement with Three Biodiesel Plants to Consolidate 6REG Signs Agreement with Three Biodiesel Plants to Consolidate 7
(Date:7/20/2015)...  Acuity Market Intelligence,s latest research "The Global ... and Privacy" forecasts that between 2014 and 2020 ... downloaded to smart mobile devices by 2.2 billion ... projected to generate more than $67.9 billion in ... period.    "Biometrics is at the ...
(Date:7/9/2015)... Calif. , July 9, 2015  Synaptics Inc. (NASDAQ: ... solutions, announced today that it will report financial results ... Thursday, July 30, 2015 after the close of market. ... analysts and investors at 2:00 p.m. PT (5:00 p.m. ... To participate on the live call, analysts ...
(Date:7/9/2015)... July 9, 2015  Synaptics Inc. (NASDAQ: ... human interface solutions, today announced a new ... fully hardware encapsulated fingerprint sensor and matching ... is literally off the grid, isolating fingerprint ... within the fingerprint sensor to provide ultimate ...
Breaking Biology News(10 mins):Biometrics on Smart Mobile Devices to Redefine Digital Identity with 12.9 Billion Biometric App Downloads between 2014 and 2020 2Synaptics to Report Fourth Quarter, Fiscal Year 2015 Results on July 30 2Synaptics Announces World's First Match-in-Sensor Fingerprint Authentication Technology 2Synaptics Announces World's First Match-in-Sensor Fingerprint Authentication Technology 3
... famed for their fallibility. Gooey glues soon lose their grip, ... feet. Geckos can cling on repeatedly to the smoothest surfaces ... the soles of their feet. Back in 2002, Kellar Autumn ... with surfaces that the reptiles ,glue, themselves on by van ...
... of ecosystems across the globe, providing water for drinking and ... life forms in rivers and streams from single-celled organisms all ... and nature itself are making it tough on rivers to ... to new research by a team of scientists including one ...
... -- Water vapor and clouds are the major contributors ... modeling study shows that the planet,s temperature ultimately depends ... The study, conducted by Andrew Lacis and colleagues at ... York, examined the nature of Earth,s greenhouse effect and ...
Cached Biology News:Humidity makes gecko feet stickier 2A river ran through it 2A river ran through it 3A river ran through it 4Carbon dioxide controls Earth's temperature 2Carbon dioxide controls Earth's temperature 3
... peptide-1(7-36) amide (GLP-1), C-terminal reactive. Cross-reacts ... <0.1% cross reactivity with the unamidated ... related peptides such as hGLP-2, glucagon, ... species. GLP-1 is identical in all ...
Human/Mouse/Rat AMPK beta 1 Affinity Purified Polyclonal Ab...
... Immunogen: Synthetic peptide derived from the N-terminal ... ZO-1. Specificity: Specific for the N-terminus ... Reactivity: Human Dog Rat Mouse (positive controls: ... mouse liver heart blood vessel and brain ...
Rabbit polyclonal to Syntrophin alpha 1 ( Abpromise for all tested applications). entrezGeneID: 6640 SwissProtID: Q13424...
Biology Products: